Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00246

Submission Number:
00246
Commenter:
Ramesh Rakholia
State:
California
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
"The PBM's practices are increasing healthcare costs to the patient and the payers (commercial and government). The discounts received due to their volume are being shared partially with the payers with the highest percent going to their bottom line." "Why should any industry have a safe harbor for kickbacks? At a time when drug prices are soaring, and the public is at risk of harm from shortages of critical medications and sterile products, the FTC MUST investigate how the middlemen of GPO and PBM are causing these issues." PBM's take it or leave it contracts which are one sided and never negotiable. sometimes PBMs pay for BRAND only medication eventhough there is a AB rated, FDA approved generic, less expensive version is available which drives health care cost for all Americans. Time has come now to stop PBMs abusive powers to independent pharmacies. THIS IS A UNFARE TRADE PRACTICE AND MUST STOP. thank you for your help and consideration.